{"id":"W4303986419","doi":"10.1111/bjh.18486","title":"Dasatinib plus <scp>Peg‐Interferon</scp> alpha 2b combination in newly diagnosed chronic phase chronic myeloid leukaemia: Results of a multicenter phase 2 study (<scp>DASA‐PegIFN</scp> study)","year":2022,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada; Merck KGaA","keywords":"Dasatinib; Medicine; Internal medicine; Neutropenia; Gastroenterology; Clinical endpoint; Adverse effect; Pegylated interferon; PEG ratio; Phases of clinical research; Immunology; Imatinib; Myeloid leukemia; Toxicity; Virus; Clinical trial","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.002332291,0.0007146833,0.002953246,0.001179418,0.0003400367,0.00008549172,0.0009582025,0.0002874861,0.0002085269],"category_scores_gemma":[0.003382438,0.0008169367,0.0005012407,0.001005605,0.0003368346,0.0004914904,0.0005933107,0.002347235,0.00002897172],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.007366287,"about_ca_system_score_gemma":0.003431619,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001478739,"about_ca_topic_score_gemma":0.002608656,"domain_scores_codex":[0.9905971,0.001697479,0.003814242,0.001042013,0.001582498,0.001266651],"domain_scores_gemma":[0.992924,0.002336745,0.002755871,0.0008902608,0.0006021818,0.0004908864],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"case_report","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.009224632,0.1708561,0.05121714,0.00169086,0.006979927,0.5901578,0.03772381,0.001974298,0.006952646,0.00005615807,0.05826272,0.0649039],"study_design_scores_gemma":[0.7055778,0.1105139,0.02817539,0.002074383,0.002239375,0.09894437,0.03807788,0.003870066,0.003765651,0.000064101,0.006336928,0.0003601969],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.984697,0.008936645,0.00007887174,0.0002137388,0.001337853,0.004080316,0.0002148753,0.00007287352,0.0003677862],"genre_scores_gemma":[0.9973153,0.0007539724,0.0001626425,0.0001370928,0.0003185798,0.0003788175,0.0002008536,0.0001465257,0.0005862561],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6963532,"threshold_uncertainty_score":0.9999544,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02136001394846421,"score_gpt":0.3168797094254256,"score_spread":0.2955196954769614,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}